Shares of GRIFOLS S A/S (NASDAQ:GRFS) have been assigned an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $19.00.
Several analysts have recently commented on GRFS shares. BidaskClub lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Santander upgraded GRIFOLS S A/S from an “underperform” rating to a “hold” rating in a report on Tuesday, October 30th. Finally, Zacks Investment Research upgraded GRIFOLS S A/S from a “sell” rating to a “hold” rating in a report on Wednesday, October 31st.
Shares of GRFS opened at $19.00 on Thursday. GRIFOLS S A/S has a 12 month low of $17.42 and a 12 month high of $24.97. The company has a quick ratio of 1.07, a current ratio of 2.78 and a debt-to-equity ratio of 1.47. The firm has a market cap of $12.65 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 1.24 and a beta of 1.07.
GRIFOLS S A/S Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Read More: Marijuana Stocks Investing Considerations
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.